Tom Powles/X
Apr 28, 2025, 16:33
Tom Powles shares final analysis results of BOND-003 trial for High-Risk NMIBC
Tom Powles, Professor at the University of London, shared a post on X:
“BOND-003: The final analysis of Intravesical Cretostimogene Grenadenorepvec (n=112). for High-Risk BCG unresponsive NMIBC with CIS. CR=75% & 12 months DFS= 50% (of ITT population). This looks in line with other adenoviral gene therapies – INFa (adstiladein).”
More posts featuring Tom Powles.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 17:28
May 29, 2025, 16:50